OpportunityAnalyzer: Ovarian Cancer - Opportunity Analysis and Forecasts to 2025

Published: May 2017
No. of Pages: 280
    ReportsandReports

OpportunityAnalyzer: Ovarian Cancer - Opportunity Analysis and Forecasts to 2025

Summary

Ovarian cancer is the fifth most common malignancy in women and is the leading cause of death among gynecological cancers. Due to the non-specific nature of disease symptoms, the majority of ovarian cancer patients are diagnosed with advanced-stage disease, at which point their prognosis is poor. Current standard of care (SOC) therapies focus on primary de-bulking surgery, followed by adjuvant platinum-based chemotherapy or neoadjuvant platinum-based chemotherapy, followed by interval de-bulking surgery and additional cycles of platinum-based chemotherapy, with carboplatin and paclitaxel being the gold standard.

In 2015, the total ovarian cancer market was valued at US$1.233B across the 7MM, with the US accounting for 47.2% of the market. Over the course of the forecast period (till 2025), GlobalData expects the 7MM sales to dramatically increase at a Compound Annual Growth Rate (CAGR) of 15%+.

The key driver of growth within the 7MM ovarian cancer market will be the establishment of new standard of care (SOC) maintenance therapies in the first and second lines of treatment for newly diagnosed and recurrent patients. The anticipated extended durations of therapy in the maintenance settings should fuel the sales of PARP inhibitors and immune checkpoint modulators, as their efficacy data is expected to justify their expensive price tags.

Major drivers of growth in the ovarian cancer market across the 7MM also include the following -
- Embracing PARP inhibitors into the treatment paradigm of patients will drive growth in the ovarian cancer market, especially through the provision of a targeted therapy option for patients leading to a more personalized approach to disease treatment.
- A significant contributor to growth in the ovarian cancer market will be the adoption of IO drugs in the treatment of the disease as the paradigm shifts toward treatment choices based on the individual patient.
- The adoption of maintenance therapy will result in patients receiving drugs for a longer duration, thereby increasing the longevity of product sales compared to those products isolated in the later lines of therapy.

The report "OpportunityAnalyzer: Ovarian Cancer - Opportunity Analysis and Forecasts to 2025" provides an overview of ovarian cancer, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.

In particular, this report provides the following analysis -
- Topline ovarian cancer market revenue from 2015-2025. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.
- Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting ovarian cancer therapeutics sales in the 7MM.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
- Analysis of the current and future market competition in the 7MM ovarian cancer therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Companies mentioned in this report: AB Science,AbbVie, Acerta, Aprea, Array BioPharma, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celsion, Chugai Pharmaceutical, Clovis Oncology, Ganymed, Genentech, Gradalis, ImmunoGen, Immunovaccine, Incyte, Innate Pharma, Janssen, Mateon Therapeutics, MedImmune, Merck & Co., Merck KGaA, Oasmia, Oncolytics Biotech, Ono Phamaceutical, Pfizer, PharmaMar, Prima BioMed, PsiOxus Therapeutics, Roche, Sotio, Taiho Pharmaceutical, Tesaro, VentiRx

Scope

- Overview of ovarian cancer, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
- Topline ovarian cancer market revenue from 2015-2025. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.
- Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting ovarian cancer therapeutics sales in the 7MM.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
- Analysis of the current and future market competition in the 7MM ovarian cancer therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the 7MM ovarian cancer therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the ovarian cancer therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Published By: GlobalData
Product Code: GlobalData40051


Did you find what you are/were looking for ? If not, read below and browse through other relevant pages for similar market research reports OR get in touch with us through the form/contact info in your right navigation panel and well share relevant market report titles for you to explore.

Related Reports:


Why ReportsnReports.com?

  • 500,000 market research reports and growing.
  • Top Fortune 500 Organizations trust us for research data.
  • 24/7 support on call as well as emails.
  • Your Details are safe with us.
  • Free support for your research requirements.
  • Report Delivery: Email
  • Delivery Time:
    • Upto 24 hrs - working days
    • Upto 48 hrs max - weekends and public holidays

Research Support / Custom Research

If this business study does not have the data and information analysis you need, contact us with your research requirements. We explore available market research reports to map your needs and share report titles with you. Alternatively, we can also offer custom research that suits your budget and timelines. Share your information requirements here.
Connect With Us
Email: sales@reportsandreports.com Call : + 1 888 391 5441

Subscription Option

Using our subscription option, you get access to market research reports and industry data of Consumer Goods market as per your needs. Get the best of Consumer Goods research reports by utilizing your research budgets in an optimum way.

More about our Subscription option
Report Alerts

Get Email alerts about market research reports from industries and publishers of your interest: